Treatment of prostate cancer with biochemical recurrence after radical prostatectomy: a case report / 中华泌尿外科杂志

As a second-generation AR antagonist, enzalutamide has shown good effects in the treatment of castration-resistant prostate cancer, and has also been used in the treatment of hormone-sensitive prostate cancer. In 2018, a patient with prostate cancer was admitted to Hangzhou First People's Hospital. After radical prostatectomy, the patients was in PSA persistence. After 29 months of endocrine therapy, the patient developed drug resistance against bicalutamide, and PSA increased month by month. PSA dropped back to undetectable after changing bicalutamide to enzalutamine.